# EDGAR Filing Document

**Accession Number:** 0001755569
**File Stem:** 0001104659-25-080213
**Filing Date:** 2025-8
**Character Count:** 10931
**Document Hash:** b4c1430a41341e5d7b4f5e83a5909771
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-080213.hdr.sgml**: 20250819

**ACCESSION NUMBER**: 0001104659-25-080213

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250819

**DATE AS OF CHANGE**: 20250819

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Marker Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001094038
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 880277072
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-58217
- **FILM NUMBER:** 251231174

**BUSINESS ADDRESS:**
- **STREET 1:** 2450 HOLCOMBE BLVD
- **STREET 2:** TMC PARTNERS OFFICE 1.311
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77021
- **BUSINESS PHONE:** (713) 400-6400

**MAIL ADDRESS:**
- **STREET 1:** 2450 HOLCOMBE BLVD
- **STREET 2:** TMC PARTNERS OFFICE 1.311
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TAPIMMUNE INC.
- **DATE OF NAME CHANGE:** 20170629

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TAPIMMUNE INC
- **DATE OF NAME CHANGE:** 20070628

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GENEMAX CORP
- **DATE OF NAME CHANGE:** 20020718
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Wilson John Robert
- **CENTRAL INDEX KEY:** 0001755569

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 33 5TH AVENUE
- **CITY:** NEW BRIGHTON
- **STATE:** MN
- **ZIP:** 55112

## Ex-99.A

**<u>Schedule A</u>**

This Schedule sets forth information with respect to each purchase and sale of Common Stock of the Issuer which were effectuated by Reporting Persons during the past sixty (60) days. All transactions were effectuated in the open market through a broker.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name of Reporting Person** | **Date of<br> Transactions** | **Type of<br> Transactions** | **Number of<br> Securities** | **Price Per<br> Share(1)** |
| John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 8/15/25 | Sale | 12922 | $1.2493 |
| John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 8/14/25 | Sale | 11869 | $1.2537 |
| John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 8/13/25 | Sale | 15918 | $1.2898 |
| John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 8/12/25 | Sale | 7100 | $1.2547 |
| John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 8/12/25 | Sale | 20000 | $1.2154 |
| John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 8/11/25 | Sale | 15377 | $1.1574 |
| John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 8/8/25 | Sale | 5300 | $1.1968 |
| John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 8/7/25 | Sale | 14546 | $1.1950 |
| John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 8/6/25 | Sale | 18267 | $1.2117 |

---

(1) The prices reported are weighted-average prices and include commissions paid in per share prices. These shares of Common Stock were purchased in multiple transactions. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC staff all information regarding the number of shares and price of each trade comprising the weighted average price and share amounts set forth in this Footnote 1.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Marker Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, Par Value $0.001**

*(Title of Class of Securities)*

**57055L107**

*(CUSIP Number)*

**John R. Wilson**<br>2100 Old Highway 8 NW<br>St. Paul MN 55112<br>651-628-9259

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/15/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **57055L107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017** | Name of reporting person<br>**John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**659901.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**659901.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**659901.00** | Aggregate amount beneficially owned by each reporting person<br>**659901.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.10%** | Percent of class represented by amount in Row (11)<br>**5.10%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** *Such percentage was calculated based upon an aggregate of 12,938,910 Issuer shares of common stock outstanding as of August 4, 2025 as represented by the Issuer's Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, Par Value $0.001

**(b) Name of Issuer:**
Marker Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE 1.311, HOUSTON, TX, 77021

This Statement on Schedule 13D (this "Schedule") relates to the common stock, par value $0.001 per share ("Common Stock"), of Marker Therapeutics, Inc., a Delaware corporation (the "Issuer"). The principal executive offices of the Issuer are located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251 Houston, Texas.

This Amendment is being filed to report that the beneficial ownership of Common Stock by the Reporting Person has decreased by more than 1% as a result of the sales reported on Schedule A.

**Item 4. Purpose of Transaction**

The information set forth under Items 3 and 6 is hereby incorporated by reference.

All of the securities of the Issuer were acquired for investment purposes. The Reporting Person sold the shares disclosed in Item 5(c) in normal and customary brokerage transactions.

The Reporting Person intends to review on a continuing basis the investment in the Issuer. Based on such review, the Reporting Person may acquire, or cause to be disposed, such securities at any time  or formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Person, the Issuer's business, financial condition and operating results, general market and industry conditions or other factors.

Except as otherwise described in this Schedule, the Reporting Person currently has no plans or proposals that relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the Board except as may be required for the Issuer to comply with exchange listing requirements with respect to the number of independent directors; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) any changes in the Issuer's charter or by-laws or other actions which may impede the acquisition or control of the Issuer by any person; (h) causing a class of securities of the Issuer to be delisted from a national securities exchange or cease to be authorized to be quoted in an interdealer quotation system of a registered national securities association; (i) causing a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) any action similar to those enumerated above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
On the date hereof, the Reporting Person beneficially owns 659,901 shares of Common Stock, which comprises 5.10% of the Common Stock of the Issuer. As of, August 4, 2025, there were 12,938,910 shares of Common Stock of the Issuer issued and outstanding as represented by the Issuer's Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2025.

**(b)**
The Reporting Person has the sole power to vote the shares beneficially owned.

**(c)**
The transactions effected during the past 60 days by the Reporting Person are set forth on Exhibit A, attached hereto.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

John R. Wilson resigned from the Issuer's Board of Directors on January 24, 2025.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017

**Signature:** /s/ John R. Wilson

**Name/Title:** John R. Wilson/Trustee

**Date:** 08/19/2025